27.3 C
New York
Thursday, June 11, 2026

Tag: stock units

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025.

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio’s recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the “Board”) and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units (“RSUs”) for 153,505 shares of common stock (together, the “Inducement Awards”). The Inducement Awards were granted as inducements material to Dr. Yarema entering into employment with ImageneBio in accordance with Nasdaq Listing Rule 5635(c)(4).

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., Aug. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass., Aug. 1, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for...

AES Reports Second Quarter 2025 Results; On Track to Deliver on 2025 Guidance and Long-Term Targets

Second Quarter 2025 Renewables SBU Adjusted EBITDA Grew 56% Versus Second Quarter 2024 Strategic Accomplishments On track to add 3.2 GW of new projects in operation in...

KLA CORPORATION REPORTS FISCAL 2025 FOURTH QUARTER AND FULL YEAR RESULTS

For the quarter, total revenues were $3.175 billion, towards the upper end of the guidance range;GAAP diluted EPS was $9.06, at the upper end...

eBay Inc. Reports Second Quarter 2025 Results

Revenue of $2.7 billion, up 6% on an as-reported basis and up 4% on an FX-Neutral basisGross Merchandise Volume ("GMV") of $19.5 billion, up...

Virtu Announces Second Quarter 2025 Results

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NYSE: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver innovative, transparent trading solutions to its clients and liquidity to the global markets, today reported results for the second quarter ended June 30, 2025.

Purple Innovation Reports Second Quarter 2025 Results; Reaffirms 2025 Guidance

Net Loss Exceeded Expectations; Adjusted EBITDA Margin Improved 120 Basis Points versus Last Year Strong Rejuvenate 2.0 Demand More than Double the Rejuvenate 1.0 Launch...

Ultra Clean Reports Second Quarter 2025 Financial Results

HAYWARD, Calif., July 28, 2025 /PRNewswire/ -- Ultra Clean Holdings, Inc. (Nasdaq: UCTT), today reported its financial results for the second quarter ended June...

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer

Galapagos versterkt managementteam met ervaren life sciences leidinggevenden om bedrijfstransformatie te versnellen

Benoemt Sooin Kwon tot Chief Business Officer en Dan Grossman tot Chief Strategy Officer

TI reports second quarter 2025 financial results and shareholder returns

DALLAS, July 22, 2025 /PRNewswire/ -- Texas Instruments Incorporated (TI) (Nasdaq: TXN) today reported second quarter revenue of $4.45 billion, net income of $1.30...

- A word from our sponsors -

spot_img
HomeTagsStock units